Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
UBS Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,250
UBS analyst Trung Huynh initiates coverage on $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and sets the target price at $1,250.According to TipRanks data, the analyst has a success rate
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,250, according to analysts by Capital IQ.Price: 1089.87, Change: +9.60, Percent Change: +
Express News | Regeneron Pharmaceuticals Inc : UBS Raises Target Price to $1250 From $1124
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:REGN) in the last three months.The following table
Regeneron Pharma Is Maintained at Overweight by Morgan Stanley
Regeneron Pharma Is Maintained at Overweight by Morgan
Express News | Regeneron Pharmaceuticals Inc : Morgan Stanley Cuts Target Price to $1,182 From $1,183
Regeneron Pharmaceuticals Hits All-time High
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183
Regeneron Pharmaceuticals (REGN) has an average rating of outperform and price targets ranging from $720 to $1,232, according to analysts by Capital IQ.Price: 1,060.00, Change: -11.12, Percent Change:
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,182
Morgan Stanley analyst Terence Flynn maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,183 to $1,182.According to TipRanks data, the analyst has
J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,150
J.P. Morgan analyst Chris Schott maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,150.According to TipRanks data, the analyst has a success rate
Regeneron Pharma Is Maintained at Overweight by Barclays
Regeneron Pharma Is Maintained at Overweight by
Express News | Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1200
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 12.03% Barclays $1050 → $1200 Maintains Overweight 06/27/2024 7.55% Canaccord Genuity $1152 → $
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050
Regeneron Pharmaceuticals (REGN) has an average outperform rating and a price target range of $720 to $1,232, according to analysts polled by Capital IQ.Price: 1053.28, Change: -0.75, Percent Change:
Express News | Regeneron Pharmaceuticals, Inc : Barclays Raises Target Price to $1200 From $1050
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Barclays analyst Carter Gould maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,050 to $1,200.According to TipRanks data, the analyst has a
Express News | Regeneron Pharmaceuticals Inc : RBC Raises Target Price to $1232 From $1229
Express News | Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K